Bizarre Patents
A portable partition for use in an automobile having a seat with a seat bench and a seat backrest.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8182836 | Abuse-resistant oral dosage forms and method of use thereof An opioid-antagonist oral dosage form which does not release a therapeutically effective amount of the opioid antagonist when the oral dosage form is orally administered to a human being, but whereby a physical alteration of the oral dosage form results in a release... | 05/22/2012 |
| 8142811 | Controlled release hydrocodone formulations A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material. ... | 03/27/2012 |
| 8092830 | Lactic acid polymer and process for producing the same A process for producing a lactic acid polymer of 15,000 to 50,000 in weight-average molecular weight, the content of polymeric materials having not more than about 5,000 in weight-average molecular weight therein being not more than about 5% by weight, characterized... | 01/10/2012 |
| 8075914 | Method and formulation for treating resistance to antihypertensives and related conditions A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount eff... | 12/13/2011 |
| 8043630 | Shell-and-core dosage form approaching zero-order drug release Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes... | 10/25/2011 |
| 8003125 | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels A cyclodextrin polymer-based injectable composition comprising cyclodextrin, a polymer which is capable of forming a hydrogel with the cyclodextrin, and a pharmacologically effective amount of at least one drug. The polymer is selected from poly(ethylene glycol), de... | 08/23/2011 |
| 7846476 | Once-a-day oxycodone formulations The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to ... | 12/07/2010 |
| 7736667 | Shell-and-core dosage form approaching zero-order drug release Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also promo... | 06/15/2010 |
| 7547452 | Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an... | 06/16/2009 |
| 7547451 | Pellet formulation for the treatment of the intestinal tract An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolera... | 06/16/2009 |
| 7510727 | Melt-extrusion multiparticulates A unit dose sustained-release oral dosage form containing a plurality of melt-extruded particles, each consisting essentially of a therapeutically active agent, one or more retardants, and an optional water-insoluble binder is disclosed. The particles have a length ... | 03/31/2009 |
| 7427413 | Stable shaped particles of crystalline organic compounds The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having... | 09/23/2008 |
| 7419504 | Poly(ester amide) block copolymers Provided herein is a copolymer that includes a soft block (A) that contains poly(ester amide) (PEA) and a hard block (B). The copolymer can be any of AB, ABA or BAB type block copolymers. By varying the relative amount of the PEA block and the hard block, one can ob... | 09/02/2008 |
| 7419686 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide ... | 09/02/2008 |
| 7417110 | Biodegradable polyphosphoramidates for controlled release of bioactive substances The present invention is directed to a series of new polycationic biodegradable polyphosphoramidates. Process for making the polymers, compositions containing these polymers and bioactive ligands to enhance the cellular uptake ad intracellular trafficking, articles ... | 08/26/2008 |
| 7408018 | Elastomeric functional biodegradable copolyester amides and copolyester urethanes The invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers are based on α-amino acids and possess physical, chemical and biodegradation properties that render them suitable for use in the ... | 08/05/2008 |
| 7384653 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent... | 06/10/2008 |
| 7374781 | Sustained release formulations containing acetaminophen and tramadol A sustained release formulation as a unit dose contains 100 mg-1000 mg of Acetaminophen and 15 mg-150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of 25%-75% of the total effective amount of drug in the dosage form and ... | 05/20/2008 |
| 7374779 | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents The present invention pertains to pharmaceutical formulations and systems for delivery of active agents, wherein a first fraction of an active agent is suspended in a vehicle and a second fraction of active agent is solubilized in the vehicle, with the suspended fra... | 05/20/2008 |
| 7368471 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) This invention provides compounds of the formula: wherein: X is a chemical bond, —CH2— or —C(O)—; R1 is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, ... | 05/06/2008 |
| 7351726 | Substituted oxadiazolidinediones The present invention relates generally to substituted oxadiazolidinediones and methods of using them. ... | 04/01/2008 |
| 7351730 | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R1, R2, R3, and R4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R8,... | 04/01/2008 |
| 7348351 | Substituted 3-alkyl and 3-arylalkyl -indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) The invention formula substituted 3-alkyl and 3-arylalkyl 1H indol-1yl acetic acid derivatives which are useful as inhibitors of plasminogen activator inhibitor (PAI-1) useful for treating fibrinolytic disorders, the compounds having the structure ... | 03/25/2008 |
| 7342039 | Substituted indole oximes The present invention relates to substituted indole oximes and methods of using them. ... | 03/11/2008 |
| 7332521 | Substituted indoles The present invention relates generally to substituted indoles such as substituted 1H-indole-2-carboxylic acid derivatives, and methods of using them. ... | 02/19/2008 |
| 7329719 | Ester-terminated poly(ester-amide) in personal care products A resin composition is prepared by reacting components comprising dibasic acid, diamine, polyol and monoalcohol, wherein (a) at least 50 equivalent percent of the dibasic acid comprises polymerized fatty acid; (b) at least 50 equivalent percent of the diamine compri... | 02/12/2008 |
| 7314640 | Formulation and process for drug loaded cores The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. ... | 01/01/2008 |
| 7304122 | Elastomeric functional biodegradable copolyester amides and copolyester urethanes The present invention provides elastomeric copolyester amides, elastomeric copolyester urethanes, and methods for making the same. The polymers that are based on α-amino acids and possess suitable physical, chemical and biodegradation properties. The polymers are u... | 12/04/2007 |
| 7303761 | Stabilised pharmaceutical composition comprising an extended release non-steroidal anti-inflammatory agent and an immediate release prostaglandin The present invention is related to a solid pharmaceutical composition comprising two separate regions, a first region comprising at least one non-steroidal anti-inflammatory drug (NSAID) and an adequate pharmaceutical carrier cont... | 12/04/2007 |
| 7304171 | Compounds and methods for cytoprotection Compounds, compositions and methods for treating degenerative diseases and disorders are disclosed, the compounds having the following structure (I): including stereoisomers, prodrugs and pharmaceutically accepta... | 12/04/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276250 | Sustained release formulations of oxymorphone Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of... | 10/02/2007 |
| 7271156 | Immunostimulatory nucleic acids The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich n... | 09/18/2007 |
| 7268159 | Substituted indoles The present invention relates generally to substituted indoles and methods of using them. ... | 09/11/2007 |
| 7265148 | Substituted pyrrole-indoles The present invention relates generally to substituted pyrrole-indoles such as substituted pyrrole-indoles, and methods of using them. ... | 09/04/2007 |
| 7259182 | Aryl, aryloxy, and aklyloxy substituted 1-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) Compounds of formula I are provided: wherein: R1, R2, and R3, are as defined herein, as well as pharmaceutical composition and methods using the compounds as inhibitors of plasminogen activator inhibitor ... | 08/21/2007 |
| 7255877 | Fenofibrate microparticles Fenofibrate microparticles are prepared using a combination of surface modifiers with a phospholipid. Particle size growth and stability are controlled while significantly smaller sized fenofibrate particles are produced. ... | 08/14/2007 |
| 7253249 | Ester-terminated poly(ester-amide) in personal care products A resin composition is prepared by reacting components comprising dibasic acid, diamine, polyol and monoalcohol, wherein (a) at least 50 equivalent percent of the dibasic acid comprises polymerized fatty acid; (b) at least 50 equivalent percent of the diamine compri... | 08/07/2007 |
| 7247491 | Method for determining release of a peptide from a sustained release polylactide formulation A method for determining the release of a peptide from a sustained release polylactide formulation which can be carried out in a shorter time than a real-time method by accelerating the release of the peptide from the formulation. It can be used to discriminate betw... | 07/24/2007 |
| 7235248 | Pharmaceutical compositions comprising cyclosporins Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva]2-Ciclosporin, in “microemulsion pre-concentrate” and microemulsion form. The compositions typically comprise (1.1) a C1-5alkyl or tetrahydrofurfuryl di- or part... | 06/26/2007 |
